A randomized controlled study of dexmedetomidine in improving liver and kidney function and oxidative stress after abdominal hyperthermic perfusion

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900026764

Enrollment

Unknown

Registered

2019-10-21

Start date

2019-07-20

Completion date

Unknown

Last updated

2019-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal cancer

Interventions

experimental group:Dexmedetomidine

control group:Normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Aged over 18 years; ASA grade I-III; no serious circulatory and neuroendocrine diseases; no preoperative infection; tumor stage; informed consent signed by patients.

Exclusion criteria

Exclusion criteria: Heart disease history: sick sinus syndrome, atrioventricular block, sinus bradycardia; long-term use of sedative and strong opioids; neurological or psychiatric disorders; known hypersensitivity to oxycodone/dexmedetomidine; any prohibition of opioid use: respiratory depression; head injury; paralytic intestinal obstruction; acute abdomen; hypercapnia; moderate to severe impairment of liver function (ALT/AST>80 U/L); severe renal impairment (creatinine clearance < 10 ml/min); chronic constipation; taking monoamine oxidase inhibitors at the same time or within 2 weeks after discontinuation; pregnancy; participants in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Superoxide Dismutase;MDA;	—

Countries

China

Contacts

Public ContactYao Yonghua

Cancer Cener of Guangzhou Medical University

yaoyonghua01@126.com+86 13711568864

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026